Frankfurt - Delayed Quote EUR

Carisma Therapeutics, Inc. (W2J.F)

0.5940

0.0000

(0.00%)

At close: January 30 at 9:59:02 AM GMT+1

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused therapeutics, today announced a strategic reprioritization of its pipeline, cessation of development of CT-0525, and a reduction in the workforce by 34%. These measures will enable Carisma to focus its resources on advancing its in vivo macrophage engineering platform for the development of fibrosis, oncology and autoimmune disease therapies. This decision aligns Carisma's efforts with next-gene

PR Newswire last month

CARM
Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Thursday, December 5th at 9:35 am ET.

PR Newswire 2 months ago

CARM
Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today presented promising preclinical data on engineered macrophages for treating liver fibrosis at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024. These results underscore the pre-clinical efficacy of Carisma's engineered macrophages in multiple liver fibrosis models and offer

PR Newswire 2 months ago

CARM
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for hepatocellular carcinoma ("HCC"), developed in collaboration with Moderna, Inc. (Nasdaq: MRNA). The data demonstrated that the development candidate can successfully crea

PR Newswire 2 months ago

MRNA

CARM
Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended September 30, 2024, and highlighted recent business updates.

PR Newswire 2 months ago

CARM
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for the treatment of hepatocellular carcinoma ("HCC"), developed in collaboration with Moderna, Inc. (Nasdaq: MRNA). The data will be presented in a p

PR Newswire 2 months ago

CARM

MRNA
Carisma Therapeutics Announces Changes to its Board of Directors

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Sohanya Cheng, MBA to the Company's Board of Directors, effective October 31, 2024. Additionally, Michael Torok has informed the Board of his intention to step down as a member, effective October 31, 2024, due to other professional commitments.

PR Newswire 3 months ago

CARM
Carisma Therapeutics Announces Upcoming Presentations at SITC 2024

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC), taking place in Houston, Texas, November 6 -10, 2024.

PR Newswire 3 months ago

CARM
Carisma Therapeutics, Moderna Expand Collaboration Into Autoimmune Diseases

Carisma Therapeutics, Moderna Expand Collaboration Into Autoimmune Diseases

PREMIUM
MT Newswires 4 months ago

CARM

MRNA
Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the expansion of its in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") collaboration with Moderna, Inc. (Nasdaq: MRNA) to include the nomination of two targets for the treatment of autoimmune diseases. Carisma retains all rights in autoimmune disease beyond the two nominated

PR Newswire 4 months ago

CARM

MRNA
Carisma Therapeutics to Present at Upcoming Conferences

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in the following upcoming conferences:

PR Newswire 4 months ago

CARM
CARISMA THERAP (CARM) Upgraded to Buy: What Does It Mean for the Stock?

CARISMA THERAP (CARM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 5 months ago

CARM
Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates

CARISMA THERAP (CARM) delivered earnings and revenue surprises of 25% and 151.97%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

CARM
Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the quarter ended June 30, 2024, and highlighted recent business updates.

PR Newswire 5 months ago

CARM

CRMIF
Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming poster presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024, taking place in San Diego, California, November 15 – 19, 2024.

PR Newswire 5 months ago

CARM
Carisma Therapeutics Announces Expansion of Its Scientific Advisory Board

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Dr. Scott Friedman and Dr. Ira Tabas to its Scientific Advisory Board (SAB). Dr. Friedman and Dr. Tabas bring extensive expertise and pioneering contributions in liver fibrosis, which will be instrumental as Carisma continues its program to develop transformative treatments for patien

PR Newswire 5 months ago

CARM
Can Carisma Therapeutics (NASDAQ:CARM) Afford To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Simply Wall St. 5 months ago

CARM
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the nomination of the first development candidate ("Development Candidate"), under its collaboration with Moderna, Inc. The Development Candidate is an in vivo CAR-M targeting Glypican-3 ("GPC3") and is designed to treat solid tumors, including hepatocellular carcinoma ("HCC"), the most prevalent type o

PR Newswire 7 months ago

CARM
Carisma Therapeutics’ solid tumour therapy obtains FDA Fast Track status

An open-label trial is currently assessing the safety, tolerability, and manufacturing feasibility of CT-0525.

Pharmaceutical Technology 7 months ago

CARM
Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum

Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Cell Therapy Forum on Tuesday, July 9th at 9:10 am ET.

PR Newswire 7 months ago

CARM

Performance Overview

Return	W2J.F	S&P 500
YTD	+38.46%	+2.26%
1-Year	-71.98%	+22.65%
3-Year	-81.14%	+36.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Carisma Therapeutics, Inc. (W2J.F)

Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline

Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024

Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma

Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024

Carisma Therapeutics Announces Changes to its Board of Directors

Carisma Therapeutics Announces Upcoming Presentations at SITC 2024

Carisma Therapeutics, Moderna Expand Collaboration Into Autoimmune Diseases

Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases

Carisma Therapeutics to Present at Upcoming Conferences

CARISMA THERAP (CARM) Upgraded to Buy: What Does It Mean for the Stock?

Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates

Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024

Carisma Therapeutics Announces Expansion of Its Scientific Advisory Board

Can Carisma Therapeutics (NASDAQ:CARM) Afford To Invest In Growth?

Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna

Carisma Therapeutics’ solid tumour therapy obtains FDA Fast Track status

Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum

Performance Overview